Hyfe is extending AI to acoustics and championing technology it claims can transform the approach to cough management, leading to improved diagnoses, better treatment and superior health outcomes. CMO Peter Small explained the rationale and how AI has inspired a significant leap forward.
Cough management has always come up short. It is one of the most common reasons people seek healthcare, and yet it has not been measurable. So says Peter Small, chief medical officer at Hyfe, a US-based start-up that is combining artificial intelligence with acoustics.
Hyfe is perfecting a technology to accurately diagnose what is really behind the coughing that sends individuals rushing to their...
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
